These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 17877933)

  • 21. Role of antiarrhythmic therapy in patients at risk for sudden cardiac death: an evidence-based review.
    Hilleman DE; Bauman AL
    Pharmacotherapy; 2001 May; 21(5):556-75. PubMed ID: 11349745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Japanese randomized trial for investigation of a combined therapy of amiodarone and implantable cardioverter defibrillator in patients with ventricular tachycardia and fibrillation: the Nippon ICD Plus Pharmachologic Option Necessity study design.
    Kurita T; Mitamura H; Aizawa Y; Nitta T; Aonuma K; Tsuboi N; Chinushi M; Kobayashi Y; Soejima K; Satomi K; Furushima H; Ohe T; Ogawa S; Kodama I; Ohtsu H; Yamazaki T;
    Circ J; 2006 Mar; 70(3):316-20. PubMed ID: 16501299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clusters of ventricular tachycardias signify impaired survival in patients with idiopathic dilated cardiomyopathy and implantable cardioverter defibrillators.
    Bänsch D; Böcker D; Brunn J; Weber M; Breithardt G; Block M
    J Am Coll Cardiol; 2000 Aug; 36(2):566-73. PubMed ID: 10933373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implanted cardioverter-defibrillators are preferable to drugs as primary therapy in sustained ventricular tachyarrhythmias.
    Saksena S; Madan N; Lewis C
    Prog Cardiovasc Dis; 1996; 38(6):445-54. PubMed ID: 8638025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of long-standing implantable cardioverter-defibrillator patients with and without appropriate therapy for ventricular arrhythmias: impact of a widening QRS.
    Dizon J; Chen K; Dizon S; Biviano A; Whang W; Ehlert F; Vazquez J; Nazif T; Garan H
    Europace; 2011 Jan; 13(1):77-81. PubMed ID: 21149513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of Antiarrhythmic Medications in Medicare Part D Patients With an Implantable Cardioverter-Defibrillator and Ventricular Tachycardia.
    Pokorney SD; Mi X; Hammill BG; Allen LaPointe NM; Curtis LH; Al-Khatib SM
    Am J Cardiol; 2017 May; 119(9):1401-1406. PubMed ID: 28341360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results of a curtailed randomized controlled trial, evaluating the efficacy and safety of azimilide in patients with implantable cardioverter-defibrillators: The SHIELD-2 trial.
    Robinson VM; Bharucha DB; Mahaffey KW; Dorian P; Kowey PR;
    Am Heart J; 2017 Mar; 185():43-51. PubMed ID: 28267474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of patients with life-threatening sustained ventricular tachyarrhythmias--the role of guided antiarrhythmic drug therapy.
    Steinbeck G; Greene HL
    Prog Cardiovasc Dis; 1996; 38(6):419-28. PubMed ID: 8638023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Electrical storm in patients with an implantable defibrillator: incidence, features, and preventive therapy: insights from a randomized trial.
    Hohnloser SH; Al-Khalidi HR; Pratt CM; Brum JM; Tatla DS; Tchou P; Dorian P;
    Eur Heart J; 2006 Dec; 27(24):3027-32. PubMed ID: 17050586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
    Hohnloser SH; Dorian P; Roberts R; Gent M; Israel CW; Fain E; Champagne J; Connolly SJ
    Circulation; 2006 Jul; 114(2):104-9. PubMed ID: 16818810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Implantable cardioverter-defibrillators for treatment of sustained ventricular arrhythmias in patients with Chagas' heart disease: comparison with a control group treated with amiodarone alone.
    Gali WL; Sarabanda AV; Baggio JM; Ferreira LG; Gomes GG; Marin-Neto JA; Junqueira LF
    Europace; 2014 May; 16(5):674-80. PubMed ID: 24481778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pharmacologic therapy of ventricular tachyarrhythmias: value of class III anti-arrhythmia drugs].
    Haverkamp W; Borggrefe M; Block M; Böcker D; Breithardt G
    Z Kardiol; 1996; 85 Suppl 6():97-106. PubMed ID: 9064989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Midlands Trial of Empirical Amiodarone versus Electrophysiology-guided Interventions and Implantable Cardioverter-defibrillators (MAVERIC): a multi-centre prospective randomised clinical trial on the secondary prevention of sudden cardiac death.
    Lau EW; Griffith MJ; Pathmanathan RK; Ng GA; Clune MM; Cooper J; Marshall HJ; Forsey PR; Stafford PJ; Gray RG; Skehan JD; Garratt CJ
    Europace; 2004 Jul; 6(4):257-66. PubMed ID: 15172648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment.
    Kühlkamp V; Mewis C; Mermi J; Bosch RF; Seipel L
    J Am Coll Cardiol; 1999 Jan; 33(1):46-52. PubMed ID: 9935007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks.
    Bunch TJ; Mahapatra S; Murdock D; Molden J; Weiss JP; May HT; Bair TL; Mader KM; Crandall BG; Day JD; Osborn JS; Muhlestein JB; Lappe DL; Anderson JL
    Pacing Clin Electrophysiol; 2011 Dec; 34(12):1600-6. PubMed ID: 21895727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effect of drug therapy on frequency of adequate discharges of implanted cardioverter defibrillator].
    Tiroke A; Ganeeva ON
    Kardiologiia; 2003; 43(6):54-8. PubMed ID: 12891312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The implantable defibrillator and antiarrhythmic drugs--competitive and complementary treatment for severe ventricular arrhythmia.
    Dorian P; Newman D
    Clin Cardiol; 1993 Nov; 16(11):827-30. PubMed ID: 8269662
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beta-blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial.
    Exner DV; Reiffel JA; Epstein AE; Ledingham R; Reiter MJ; Yao Q; Duff HJ; Follmann D; Schron E; Greene HL; Carlson MD; Brodsky MA; Akiyama T; Baessler C; Anderson JL
    J Am Coll Cardiol; 1999 Aug; 34(2):325-33. PubMed ID: 10440140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Empiric antiarrhythmic drug therapy in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia: pragmatism or anachronism?
    Mitchell LB
    J Am Coll Cardiol; 2009 Aug; 54(7):616-7. PubMed ID: 19660691
    [No Abstract]   [Full Text] [Related]  

  • 40. Significance and control of cardiac arrhythmias in patients with congestive cardiac failure.
    Singh BN
    Heart Fail Rev; 2002 Jul; 7(3):285-300. PubMed ID: 12215733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.